Experion Biotechnologies Inc. develops and distributes premium high value cannabis products, With a and passionate and engaged team they are able to make quick and effective market driven decisions, to quickly create and distribute best in class products. But should you buy Experion Stock?
The company develops trendsetting, first to market genetics and premium cannabis products under a highly regarded Citizen Stash brand which is distributed across Canada. Experion expands capacity with strategic grow and supply partners to cultivate and process under unique specifications. Experion ensures quality control by executing all final processing, packaging and labeling within licensed facilities and then distributing these products through a robust network across Canada.
Seems a sound business model but should you buy Experion stock? Let’s dive into the fundamentals:
Experion Holdings Fundamentals
HQ: Mission, BC, Canada
Symbol: EXP (TSX), EXPFF (OTC), MB31 (Frankfurt)
Experion Holdings is the parent company to Experion Biotechnologies, a Health Canada licensed cultivator and processor of cannabis. They traditionally have focused on making revenue models scalable through distribution agreements.
Market Cap: US $29.2
Enterprise Value: $26.8
# of employees: 354
Majority Subsidiaries: EFX Laboratories Inc.
Cultivation: 2,500 kgs per year of cultivation with capacity to process 4,000 kgs per year of flower and pre-rolls. They have over 75 strains in their genetic bank.
They serve 7 provinces with access to over 600 retail locations throughout Canada. They have an increasing number of SKUs with very strong pre-roll sales.
Vertically integrated: Yes
Horizontally diversified: No
Revenue (ttm): $8.87 million
Outstanding shares (diluted): 100.76 million
WATCH: Experion Technical Analysis
CEO: Jarrett Malnarick
CFO: Kerry Biggs
VP Sales/Marketing: Daryn Medwid
VP Facilities/IT: Leo Wong
CEO Malnarick comes from the food and beverage, natural health, pharma, and agriculture industries. He also has cannabis experience from Washington and Oregon. Mr. Biggs comes from lululemon athletica.
Citizen Stash is their premium retail brand. Kanabe Goods is their medical brand. Both are carried as craft brands. They will release cannabis 2.0 products in 2021 (edibles, topicals etc).
Current share price: US $0.300
52 week high/low: $0.075-0.495
Price to Sales: 3.29
As of Feb. 28th, 2021 they had cash and cash equivalents of $1.28 million CAD, $13.29 million CAD in total assets with $1.58 million CAD of liabilities. They have $3 million CAD in long term debt.
The risks of investing in any cannabis company are very high given the immaturity of the market and all the Canadian competitors. The risk of investing in Experion are somewhat lessened by their growing QoQ sales growth and strong brands.
Bottom Line: Should You Buy Experion Stock?
Experion Holdings is a vertically integrated cultivator of craft cannabis under the Citizen Stash and Kanabe brands. They have products distributed in 7 provinces in the very competitive Canadian market.
They are one of the smaller players in Canada but there is plenty to like about them. They’ve had six consecutive quarters of sales growth, most recently with $4.06 million CAD in the quarter ending in Feb. 28, 2021 (53% increase QoQ and 405% increase over the same quarter in 2020). Interestingly they achieve $8 CAD per gram, which is above the average in Canada.
They are also on the cusp of profitability, something not many of their competitors can claim. Their first positive adjusted EBITDA happened in early 2021 and net losses were only around $90,000 CAD. If they can continue to grow sales and exhibit financial health, they may be ripe for M&A activity.
Their P/S, P/B, and EV/Revenue are all very competitive and the company is alright on cash flow. Experion stock is likely undervalued now. They announced they are changing their name to Citizen Stash Cannabis Corp to attempt to capitalize on their leading brand. This likely will be received positively by the market as Experion isn’t exactly a memorable name.
For all these reasons, we give them a Strong rating for 2021. Look for the stock price to increase and for them to continue becoming more profitable prior to larger companies noticing and attempting to pick them up.
Should You Buy Experion Stock?
About Cannin: Your Cannabis Stocks Resource
78% of Cannin’s fundamentals prove true within 30 days or less on 100+ recommendations over the past 2 years.
Cannin is your #1 trusted resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. We aggregate hundreds of hours of financial research and provide tips on the best cannabis stocks for 2021.
Use Cannin as your resource for:
Market analysts expect the marijuana and hemp industry will have an annual value exceeding $75 Billion in the next decade. Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.
Are you looking to buy stock in hemp companies or marijuana companies for 2021? Interested in new penny hemp stock companies? Looking for the best Canadian cannabis stocks to invest in? Looking to leverage the power of algorithmic stock trading to beat the cannabis market? We can help.
Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.
- +30% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
We’re so confident you’ll love our algotrading cannabis stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best cannabis stocks – we’ll show you how at cannin.com.